Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Pathophysiology

Background:

• Pathological cardiac hypertrophy is a significant risk factor for heart failure and sudden death.
• Current treatments for cardiac hypertrophy offer limited efficacy, primarily managing symptoms.
• Understanding the molecular mechanisms driving cardiac hypertrophy is crucial for developing effective therapies.

Purpose of the Study:

• To review active substances and signaling pathways involved in cardiac hypertrophy pathogenesis.
• To focus on the roles of transforming growth factor-β (TGF-β) and bone morphogenetic protein (BMP) signaling.
• To identify potential molecular targets for precise intervention in cardiac hypertrophy.

Main Methods:

• Literature review summarizing research on cardiac hypertrophy.
• Analysis of signaling pathways implicated in cardiac hypertrophy development.
• Identification of key molecules for potential therapeutic targeting.

Main Results:

• Multiple active substances and signaling pathways contribute to cardiac hypertrophy.
• TGF-β and BMP signaling pathways play critical roles in cardiac hypertrophy progression.
• Specific signaling molecules show potential as targets for molecular intervention.

Conclusions:

• Elucidating molecular pathways is key to advancing cardiac hypertrophy treatment.
• TGF-β and BMP signaling offer promising targets for novel therapeutic strategies.
• Identifying clinically valuable signaling molecules can lead to precise treatment and improved patient outcomes.